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Abstract
Background: An important consideration when analyzing both microarray and quantitative PCR expression data is
the selection of appropriate genes as endogenous controls or reference genes. This step is especially critical when
identifying genes differentially expressed between datasets. Moreover, reference genes suitable in one context (e.g.
lung cancer) may not be suitable in another (e.g. breast cancer). Currently, the main approach to identify reference
genes involves the mining of expression microarray data for highly expressed and relatively constant transcripts
across a sample set. A caveat here is the requirement for transcript normalization prior to analysis, and
measurements obtained are relative, not absolute. Alternatively, as sequencing-based technologies provide digital
quantitative output, absolute quantification ensues, and reference gene identification becomes more accurate.
Methods: Serial analysis of gene expression (SAGE) profiles of non-malignant and malignant lung samples were
compared using a permutation test to identify the most stably expressed genes across all samples. Subsequently,
the specificity of the reference genes was evaluated across multiple tissue types, their constancy of expression was
assessed using quantitative RT-PCR (qPCR), and their impact on differential expression analysis of microarray data
was evaluated.
Results: We show that (i) conventional references genes such as ACTB and GAPDH are highly variable between
cancerous and non-cancerous samples, (ii) reference genes identified for lung cancer do not perform well for other
cancer types (breast and brain), (iii) reference genes identified through SAGE show low variability using qPCR in a
different cohort of samples, and (iv) normalization of a lung cancer gene expression microarray dataset with or
without our reference genes, yields different results for differential gene expression and subsequent analyses.
Specifically, key established pathways in lung cancer exhibit higher statistical significance using a dataset
normalized with our reference genes relative to normalization without using our reference genes.
Conclusions: Our analyses found NDUFA1, RPL19, RAB5C, and RPS18 to occupy the top ranking positions among 15
suitable reference genes optimal for normalization of lung tissue expression data. Significantly, the approach used
in this study can be applied to data generated using new generation sequencing platforms for the identification of
reference genes optimal within diverse contexts.
Background
Gene expression profiling, including quantitative RT-
PCR (qPCR) and microarray experimentation, is invalu-
able for the molecular analysis of biological systems.
The interpretation of results from such experiments (i.
e., the determination of differential expression for a
particular gene among datasets) is strongly influenced
by the selection of reference genes for normalization
across datasets [1]. Specifically, gene expression is nor-
malized within a given dataset by calculating the tran-
script abundance of the gene of interest relative to a
gene that is constantly expressed across independent
datasets (termed a “housekeeping” or a “reference”
gene), and differential expression between two datasets
or samples is determined by calculating the ratio of the
normalized expression levels for the gene of interest
between the two datasets. Typically, housekeeping genes
* Correspondence: rchari@bccrc.ca
† Contributed equally
1Department of Integrative Oncology, British Columbia Cancer Agency
Research Centre, Vancouver, BC, Canada
Full list of author information is available at the end of the article
Chari et al. BMC Medical Genomics 2010, 3:32
http://www.biomedcentral.com/1755-8794/3/32
© 2010 Chari et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.satisfy the following criteria: they are highly expressed in
the cell, the variability in expression between samples is
minimal, and the genes’ expression is not influenced by
the experimental conditions tested [2]. Hence, problems
arise when housekeeping genes are selected that do not
meet these criteria, as fluctuations in these genes may
erroneously influence the data interpretation.
Historically, beta actin (ACTB), glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), and 18 S rRNA have
been routinely used as reference genes for qPCR and
microarray data normalization. However, a number of
studies have shown that expression of these genes varies
considerably depending on the specific tissue type and
disease state of the tissue [3-16]. Attempts to achieve
more reliable normalization include the spiking of syn-
thetic poly-A RNAs for the analysis of cDNA arrays and
northern blots, and the combined use of an oligo-(dT)n
primer with an 18 S specific primer for qPCR analysis
[17,18]. In addition, re-mining of large microarray data-
sets for the identification of novel, highly stable genes,
as well as use of a combination of reference genes
i n s t e a do fas i n g l eg e n ef o rn o r m a l i z a t i o n ,a r es o m eo f
the other approaches taken to address this problem
[11,13,19].
Recently, efforts have been made to identify more sui-
table reference genes for microarray and qPCR studies
of lung cancer. Specifically, candidate reference genes
have been identified from the mining of microarray
gene expression data to identify the least variable genes,
followed by validation of expression using qPCR
[11,20,21]. However, as microarray data do not provide
absolute abundance values for transcripts, selection of
reference genes from this type of data is inherently pro-
blematic. To circumvent this handicap in the utilization
of microarray data, we turn to the use of large-scale
expression profiling permitted by serial analysis of gene
expression (SAGE) experimentation for the identifica-
tion of novel reference genes optimal for the study of
lung cancer. This approach, which we have termed nor-
malization of expression by permutation of SAGE
(NEPS), takes advantage of the fact that SAGE is a tran-
scriptome profiling technique that identifies the absolute
abundance levels of transcripts by direct enumeration of
sequence tag counts, thus allowing the direct compari-
son of expression levels across multiple profiles without
the need for reference or housekeeping genes [22].
NEPS adopts a permutation test approach designed
for analyzing relatively small sample sizes, such as those
typically encountered with SAGE. Unlike the conven-
tional T-test, the permutation test is non-parametric
[23]. The null hypothesis states that the mean gene
expression levels in two groups of SAGE libraries being
compared (in this case normal and cancer), are the
same. For this analysis, samples from both the normal
and the cancer groups are pooled, followed by random
sampling to create a simulated Group 1 and a simulated
Group 2. For each gene, the difference in expression
between these two simulated groups was measured.
This exercise was repeated 10,000 times, thus generat-
ing a simulated mean μ and a simulated standard devia-
tion s.T h epermutation score (PS) of a given gene is
defined by PS
O =
− || 
 ,w h e r eO i st h et r u ed i f f e r e n c e
between the average expression levels in the two groups.
Hence, for a given gene, the closer the permutation
score is to zero, the more it satisfies the constancy
requirement.
To demonstrate the utility of NEPS for selecting genes
that satisfy the constancy requirement, we analyzed 24
bronchial epithelial lung SAGE libraries, 2 lung parench-
yma libraries, and 11 lung squamous cell carcinoma
libraries. From this analysis, NEPS selected 15 genes,
which we hereafter refer to as the lung-NEPS reference
genes (Table 1). We further demonstrate that (1) while
these genes perform well as reference genes for lung,
they are not satisfactory for normalization of expression
data from other tissues, suggesting that reference genes
are tissue-specific, and (2) in lung cancer datasets, dif-
ferential gene expression determination and subsequent
pathway analyses are improved after normalization using
the lung-NEPS reference genes.
Methods
SAGE library construction
26 normal and 11 lung cancer SAGE libraries were con-
structed and used in the analysis [24]. The construction
of the 26 normal libraries has been previously described
[25,26]. 24 of these libraries were generated from exfo-
liated bronchial cells obtained from bronchial brushes,
and two libraries from normal lung parenchyma (Addi-
tional file 1). Conversely, the 11 cancer libraries were
generated from biopsied specimens with six libraries
representing lung squamous cell carcinoma and five
libraries representing carcinoma in situ. This data can
be found at the GEO database with the following series
accession numbers: GSE3707, GSE5473, and GSE7898.
All samples were acquired under approval by the Uni-
versity of British Columbia - British Columbia Cancer
Agency Research Ethics Board (UBC-BCCA-REB) and
all subjects provided written consent.
SAGE data from public domain
Publicly available SAGE data were also used in this ana-
lysis, representing both brain and breast cancer. Specifi-
cally, six normal and 12 breast cancer libraries
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libraries were used (Additional file 3). The libraries were
obtained from the cancer genome anatomy project
(CGAP) database http://cgap.nci.nih.gov[27,28].
Permutation test
Given that SAGE libraries are expensive to generate, the
number of libraries in a given study is typically small
(i.e., in 10’s, rather than in 100’s). The permutation test
is a non-parametric test, which does not assume any
underlying distribution. The number of samples
required for the test to achieve sufficient statistical
power is relatively low compared to other statistical
tests (e.g., t-test and c
2-square test). Furthermore, each
additional sample increases the power of the test expo-
nentially. The permutation test is a test of the means
between two different distributions. Without loss of gen-
erality, let us assume that one distribution is for the
gene expression level of a particular gene in normal tis-
sues (i.e. subscript n), and that the other distribution is
for cancerous tissues (i.e. subscript c). Genes are
selected using the following hypotheses:
Null Hypothesis
Alternative Hypothesis
H
H
cn
ac n
:
:


−=
−≠
0
0
If there is little difference between the two means, it
would make no difference if we mix the cancerous sam-
ples with the normal samples. But, if the null hypothesis
is rejected, it indicates that the gene expression levels of
normal and cancer samples are sufficiently different (the
alternative hypothesis). In the following, we show our
specific implementation of the test. Let n and c be the
number of normal tissue samples and the number of
cancerous tissue samples respectively.
A. For each gene, select all the gene-specific normal-
ized tag counts from the normal libraries and all the
gene-specific normalized tag counts from the cancer
libraries.
B. Randomly select n counts to create a simulated
normal set, and calculate the simulated normal mean
μsn.
C. Similarly, select the remaining c counts form the
simulated cancerous set. Calculate the simulated cancer
mean μsc.
D. Consider the random variable v = μsc - μsn, called
the simulated difference.
E. Repeat the steps A to D above m times. Let μ and
s denote the mean and the standard deviation of v.
F. Now separate the libraries back into their true iden-
tity: normal or cancerous. Calculate the true observed
difference O = μrc - μrn,w h e r eμrc denotes the true
mean count of the cancerous libraries, and μrn denotes
the true mean of the normal libraries.
G. Calculate the Permutation Score PS where
PS
O =
− || 
 .
H. Repeat all the above steps for each gene. Sort the
permutation score in descending order.
T h ep e r m u t a t i o ns c o r ei so n ew a yt om e a s u r eh o w
likely the actual observed difference occurs by chance. It
is based on standardization, i.e., subtracting the mean
and then divided by the standard deviation. The more
Table 1 Lung NEPS Genes
Gene Symbol Gene Name Average Raw Tag Count
1 Permutation Score
PPP1CB protein phosphatase 1, catalytic subunit, beta isoform 29 0.003
B2M beta-2-microglobulin 829 0.011
CSTB cystatin B (stefin B) 52 0.036
RPL4 ribosomal protein L4 46 0.045
SLFN13 schlafen family member 13 31 0.045
CAPZB capping protein (actin filament) muscle Z-line, beta 77 0.050
ATP5J ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6 38 0.059
RAB5C RAB5C, member RAS oncogene family 44 0.064
NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5 kDa 89 0.077
RPL19 ribosomal protein L19 69 0.082
HMGB1 high-mobility group box 1 39 0.087
CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 27 0.100
RPS18 ribosomal protein S18 112 0.123
HSPA1A heat shock 70 kDa protein 1A 40 0.133
EIF4A2 eukaryotic translation initiation factor 4A, isoform 2 89 0.145
1Across all normal and cancer SAGE libraries
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(expressed as multiples of the standard deviation), the
less likely that the true observed difference is a coinci-
dence. That is to say, the larger the permutation score,
the more significant is the observed difference between
cancerous and normal samples.
On the other hand, for the sake of evaluating the con-
stancy requirement, the ideal reference gene would have
a permutation score equal to 0. This means that there is
no difference in the distributions of expression levels
between cancerous and normal samples. For the results
reported here, we used m = 10,000 permutations.
Data pre-processing
Raw tag counts for each SAGE library were normalized
to tags per million (TPM) to facilitate adequate compar-
ison among libraries. Tag-to-gene mapping was per-
formed using the February 5
th, 2007 version of
SAGEGenie [27]. In cases where multiple SAGE tags
mapped to the same gene, the tags were collapsed to
capture all potential transcript variants, and a cumula-
tive tag count was utilized for analysis.
Statistical criteria for reference gene selection
The permutation test outlined above was used to iden-
tify genes which were statistically similar when compar-
ing the libraries from normal tissue (bronchial
epithelium and lung parenchyma) and cancerous tissue
of the lung. Three main criteria were used for reference
gene selection: permutation score (described above) ≤
0.15; at least two SAGE tags observed in each library;
and an overall average count of ≥ 25 across all samples.
For the analysis in brain and breast tissue, the first two
criteria were maintained, but due to the lower sequen-
cing depth, an average count of ≥ 10 across all samples
was used instead.
Quantitative RT-PCR validation in clinical lung cancer
specimens
One microgram of total RNA from 15 lung tumor and
matched non-malignant parenchyma samples were con-
verted to cDNA using the High-Capacity cDNA archive
kit (Applied Biosystems Inc., Foster City CA). One hun-
dred nanograms of cDNA were utilized for qPCR using
the TaqMan Gene Expression Assay (Applied Biosys-
tems Inc). All fifteen lung NEPS genes and six addi-
tional reference genes were assayed. All TaqMan probes
were pre-optimized by Applied Biosystems. Primer IDs
for all genes are provided in Additional file 4. The 30
samples were assayed in triplicate in parallel along with
negative (no cDNA template) controls using the 7500
Fast Real-Time PCR System. Appropriate cDNA
dilutions were used such that the exponential phase of
the amplification curves were within the 40 PCR cycles
recommended by the manufacturer (i.e. ranging from
16-36 cycles for the 20 genes and 1-13 cycles for
18SRNA). Cycle thresholds were determined from
amplification curves using 7500 Fast System software.
For the analysis of qPCR data, three different methods
were used. Within each method, all genes were ranked
from best to worst. Subsequently, for each gene, a
cumulative ranking across all three methods was deter-
mined by summing its rank from each individual
method. Two previously published methods, geNorm
[14] and NormFinder [29], and the variance of cycle
threshold difference (dCt) across all 15 tumor/matched
non-malignant sample pairs were the approaches used
to determine constancy.
Analysis of publicly available microarray datasets
Lung NEPS genes were used to re-normalize two pub-
licly available microarray datasets. Microarray data were
obtained from GEO at NCBI under accession numbers
GSE10072 [30] and GSE12428 [31].
For the Affymetrix data (GSE10072), Raw CEL files
were processed through Affymetrix’s Microarray Array
Suite (MAS) 5.0 algorithm in the “affy” package in Bio-
conductor [32,33]. Briefly, MAS 5.0 is a three step pro-
cess which involves a global background signal
correction, correction of the probe value for cross-hybri-
dization and spurious signals using mismatch probes
which are off by one base, and finally, scale normaliza-
tion of each experiment to a fixed median intensity to
facilitate inter-experimental comparison http://media.
affymetrix.com/support/technical/whitepapers/sadd_whi-
tepaper.pdf. Probes were filtered on MAS 5.0 calls, and
those having a “P” or “M” call in at least 50% of samples
were retained. This resulted in a dataset of 11440
probes. Of the 15 lung NEPS reference genes, 12 were
represented on the array platform. Of those 12 genes,
probes which had a “P” call in 100% of the samples
were used for the calculation of the scaling factor with
only one probe/gene allowed. If two probes met these
criteria for one gene, the probe with the highest mean
expression was chosen. After employing these criteria,
eight probes were used (Additional file 5), which repre-
sented genes PPP1CB, B2M, RPL4, CAPZB, ATP5J,
RAB5C, NDUFA1, and HSPA1A.
For the Agilent microarray data (GSE12428), all lung
NEPS genes were represented on this microarray plat-
form. Data was processed as described previously [31]. In
the cases where lung NEPS genes were represented with
multiple probes, the probe with the maximum average
intensity across the dataset was used. A list of the probes
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at least two replicate experiments, the average across
replicate experiments was used for each probe.
To determine the scaling factor, for each sample, lin-
ear regression analysis was performed comparing the
values for the reference gene (x) versus the average
values for the reference genes across the sample set (y).
The slope of the line based on least-squares fitting was
then multiplied to each value in the experiment.
Next, Significance Analysis of Microarrays (SAM) was
performed to determine differentially expressed genes
between non-malignant and malignant samples for both
microarray datasets using the “samr” package in R [34].
Unpaired analysis was performed using the normal sam-
ples versus tumor samples and the delta parameter set to
0.4. Probes which had a Q-value% ≤ 5 were considered sig-
nificant. For the Affymetrix dataset, results were compared
between the dataset normalized with MAS 5.0 alone and
MAS 5.0 + NEPS scaling and for the Agilent dataset, the
comparison was done between median normalization
alone and NEPS scaling followed by median
normalization.
Results and Discussion
Identification of reference genes for gene expression
analysis in lung cancer
From our NEPS analysis [with an imposed permutation
score (PS) threshold ≤ 0.15, and an average expression
of ≥ 25 raw tag counts across all samples], 15 genes
were identified as the most consistently expressed
across normal and cancerous lung tissue (Table 1).
Here we identified beta-2-microglobulin (B2M), com-
ponents of the large ribosomal subunit such as riboso-
mal protein L19 (RPL19)a n dribosomal protein L4
(RPL4), components of the small ribosomal subunit
such as ribosomal protein S18 (RPS18), and electron
transport chain constituents such as NADH dehydro-
genase (ubiquinone) 1 alpha subcomplex 1 (NDUFA1),
to rate highly in our permutation analysis, thereby sug-
gesting their potential as reliable reference genes. B2
M has previously been utilized as a reference gene
[10,15], providing validity to the approach used here.
The 18 S and 28 S rRNAs have previously served as
reference genes [4,7,11,12,16], and here we show that
the ribosomal protein genes can also provide this
service.
Performance of standard and previously reported
reference genes
A previous study reported a meta-analysis of microar-
ray data designed to identify novel reference genes for
the study of non-small cell lung cancer (NSCLC) [11].
Using a small panel of tumor/normal specimens, the
authors demonstrated that genes commonly used for
reference in qPCR experimentation were sub-optimal,
and identified novel, more consistently expressed
genes to be superior as reference genes. Additionally,
studies of asthmatic airways have also shown that tra-
ditional reference genes such as ACTB and GAPDH
perform poorly in this regard [6,7,12,14,15]. We find
similar results using our NEPS-based approach. As
described above, genes such as B2 M (permutation
score = 0.011) and RPL19 (0.082) were shown to have
very low permutation scores denoting stable expres-
sion between normal and cancer, whereas ACTB
(2.69) and GAPDH (6.48) performed very poorly with
significant differential expression. Other known refer-
ence genes such as hypoxanthine phosphoribosyltrans-
ferase 1 (HPRT1) (0.114) and TATA box binding
protein (TBP) (0.468), while exhibiting low permuta-
tion scores, were not as highly expressed with average
raw tag counts across all samples of 1.54 and 1.65,
respectively. In contrast, genes such as peptidylprolyl
isomerase A (PPIA, aka cyclophilin A) (6.11), transfer-
rin receptor (TFRC, p90, CD71) (4.70), and phospho-
glycerate kinase 1 (PGK1) (5.04) identified in a
microarray meta-analysis study (see above) [11], per-
formed poorly in our study, as revealed by the rela-
tively high permutation scores. Although these
particular genes did not perform as well as the refer-
ence genes identified from our permutation analysis,
other genes identified by Saviozzi et al., such as signal
transducer and activator of transcription 1 (STAT1)
(0.21), esterase D/formylglutathione hydrolase (ESD)
(0.18), Yes-associated protein 1 (YAP1)( 0 . 6 5 )a n dpoly-
merase (RNA) II (DNA directed) polypeptide A
(POLR2A) (0.88) did perform satisfactorily in our
study, as evidenced by permutation scores ≤ 1. In addi-
tion to these genes, a second set of genes identified
using a cross-tissue and cross-platform analysis were
also assessed [20] and similarly, while some genes such
as C-terminal binding protein 1( CTBP1), cullin 1
(CUL1), DIM1 dimethyladenosine transferase 1-like
(DIMT1L), tripartite motif-containing 27 (TRIM27)a n d
ubiquilin 1 (UBQLN1) performed reasonably well
based on our metric, others such as poly(A) polymerase
alpha (PAPOLA)a n dADP-ribosylation factor-like 8B
(ARL8B) did not (Figure 1, Additional file 7).
Demonstrating tissue specificity of reference genes
To further our investigations regarding reference genes
optimal for cancer cell biology, we expanded our ana-
lysis to include publicly available SAGE libraries repre-
senting normal and cancer tissue from both brain and
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that the reference genes identified in the lung dataset
a r ed i s t i n c tf r o mt h o s ef o u n di ne i t h e rb r e a s t( T a b l e2 )
or brain (Table 3). This data strongly suggests that
reference genes should be selected in a tissue specific
manner. For example, GAPDH,w h i c hp e r f o r m e d
poorly as a reference gene for lung gene expression
analysis (see above), was in fact one of the best refer-
ence genes identified from the analysis of the brain
dataset (Table 3). Moreover, not only was there no
overlap among the reference gene lists determined for
each of the three different tissue types (i.e., lung-NEPS,
breast-NEPS,b r a i n - NEPS), but when examining
reference genes specific to o n et i s s u et y p e( i . e .l u n g -
NEPS) in the other two tissue types (i.e. breast or
brain), the permutation scores for these genes were
significantly higher and more variable (Figure 2). These
results are consistent with other studies demonstrating
the need for tissue and context-specific selection of
reference genes [3,5,8,10,14].
Quantitative RT-PCR validation of identified reference
genes in lung cancer samples
Using a secondary set of 15 tumor and matched non-
malignant samples, qPCR was used to validate consis-
tency of expression for all lung-NEPS genes.
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Figure 1 Enhanced performance of the lung-NEPS genes (red; see Table 1) relative to previously reported and standard reference
genes traditionally used in qPCR and microarray normalization (blue). The x-axis represents the permutation score of a defined gene and
the y-axis represents the average raw (non-normalized) tag count for the same gene. Data used in the graph are given in Additional file 7. Lung
NEPS genes are stable and highly expressed as compared to the traditionally used genes. B2 M appears to perform the best with respect to high
average tag count and low permutation score. Notably, the gene that performs the poorest is GAPDH.
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fied, commonly used housekeeping genes ACTB,
GAPDH, HPRT1,a n dTBP. In addition, two genes out
of 13 identified (CUL1 and TRIM27) as suitable refer-
ence genes from a previously published study [20], were
selected here based on high NEPS performance (see
above), for qPCR analysis.
Of the NEPS genes analyzed, NDUFA1, RPL19,
RAB5C, member RAS oncogene family (RAB5C), and
RPS18 performed the best based on the cumulative
ranking metric (Table 4). Conversely, the standard refer-
ence genes ACTB, GAPDH, and HPRT1 did not perform
as well. These results confirm a high constancy of
expression for a subset of the lung-NEPS genes using an
alternative method in a secondary set of samples.
Effect of reference genes on differential gene expression
analysis
Using a publicly available microarray dataset
(GSE10072, [30]), differential expression analysis was
performed using SAM [34]. Results from SAM were
compared using the dataset normalized by MAS 5.0
alone, versus the same dataset normalized by MAS 5.0
with scale normalization using the lung-NEPS
Table 2 Breast NEPS Genes
Gene
Symbol
Gene Name Average Raw Tag
Count
Permutation
Score
EIF5A eukaryotic translation initiation factor 5A 22 0.003
EIF3S2 eukaryotic translation initiation factor 3, subunit 2 beta, 36 kDa 12 0.037
RPS8 ribosomal protein S8 122 0.046
TSPAN9 tetraspanin 9 122 0.051
UBB ubiquitin B 39 0.057
RPL28 ribosomal protein L28 78 0.064
FTL ferritin, light polypeptide 16 0.066
YWHAQ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta
polypeptide
19 0.074
TMEM49 transmembrane protein 49 13 0.083
FAM39B family with sequence similarity 39, member B 11 0.091
NINJ1 ninjurin 1 13 0.097
RPL30 ribosomal protein L30 108 0.108
PDE6B phosphodiesterase 6B, cGMP-specific, rod, beta 10 0.115
TUBA3 tubulin, alpha 1a 50 0.117
MYL9 myosin, light chain 9, regulatory 15 0.120
MYH9 myosin, heavy chain 9, non-muscle 21 0.128
NPM1 nucleophosmin (nucleolar phosphoprotein B23, numatrin) 48 0.130
HLA-A major histocompatibility complex, class I, A 45 0.131
RPS2 ribosomal protein S2 63 0.138
Table 3 Brain NEPS Genes
Gene Symbol Gene Name Average Raw Tag Count Permutation Score
NUCKS1 nuclear casein kinase and cyclin-dependent kinase substrate 1 14 0.024
CDAN1 congenital dyserythropoietic anemia, type I 35 0.030
PABPCP2 poly(A) binding protein, cytoplasmic, pseudogene 2 15 0.033
GTF2I general transcription factor II, i 22 0.036
ZFAND5 zinc finger, AN1-type domain 5 20 0.060
GAPDH glyceraldehyde-3-phosphate dehydrogenase 163 0.068
NCL nucleolin 13 0.083
FIS1 fission 1 (mitochondrial outer membrane) homolog (S. cerevisiae) 10 0.094
GRIN2C glutamate receptor, ionotropic, N-methyl D-aspartate 2C 81 0.132
RPS27A ribosomal protein S27a 63 0.142
COX4I1 cytochrome c oxidase subunit IV isoform 1 17 0.148
CXXC5 CXXC finger 5 13 0.149
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observed differences in the total number of differen-
tially regulated genes, depending on the normalization
protocol used. When MAS 5.0 + NEPS normalization
w a su s e d ,5 5 0 2g e n e sw e r ei d e n t i f i e da su p - r e g u l a t e d
in cancer, whereas 4798 up-regulated genes were iden-
tified using MAS 5.0 alone. With respect to down-
regulated genes, 2543 were identified using MAS 5.0 +
NEPS, whereas 3325 were identified using MAS 5.0
alone (Figure 3A). According to the Canonical Path-
way Analysis [Ingenuity Pathway Analysis (IPA)], we
observe slight differences in both the number and the
significance of identified pathways between the two
sets of differentially normalized microarray data (Addi-
tional file 8). For example, while both datasets identify
pathways such as mitochondrial dysfunction and pro-
tein ubiquitination, analysis of the dataset normalized
by MAS 5.0 + NEPS identifies pathways known to be
important in lung cancer, such as Neuregulin and
JAK/Stat [35], at a higher significance relative to ana-
lysis of the same dataset normalized by MAS 5.0
alone (Figure 3B). Similarly, when evaluated using an
additional publicly available lung cancer microarray
dataset [31], we observe slight differences between the
various pathways identified from analysis of differen-
tially expressed genes derived from a NEPS-normal-
ized dataset versus a dataset not normalized using the
lung-NEPS genes (Additional file 9, Additional file
10). These results demonstrate that the choice of
reference genes used for data normalization can influ-
ence the conclusions derived from gene expression
studies.
Conclusions
I nt h i ss t u d yw ep r e s e n tam e t h o d o l o g yb a s e du p o n
permutation test analysis of SAGE data, to identify
reference genes that more stringently satisfy the con-
stancy requirements crucial for accurate normalization
between samples utilized in gene expression experi-
ments. Specifically, we have identified reference genes
more effective for normalization than the traditional
and previously reported housekeeping genes for lung,
breast, and brain cancer gene expression profiling.
Furthermore, we strongly emphasize that reference
genes utilized for expression profiling should be
selected in a tissue specific manner. Given that this
methodology utilizes sequence-based data, its utility
will increase as data generated from new next-genera-
tion sequencing platforms accumulate. The usage of
more appropriate reference genes will have an impact
on the interpretation of existing microarray data as
well as expression data generated in future studies, and
potentially will shed new insight into the molecular
biology of cancer.
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Figure 2 Tissue-specificity of reference genes.C o m p a r i s o no f
the permutation scores for reference genes generated in one tissue
type with permutation scores for the same genes in the other two
tissue types. (A) Performance of lung-NEPS genes in breast and
brain tissues, (B) Performance of breast-NEPS genes in lung and
brain tissues, and (C) Performance of brain-NEPS genes in lung and
breast tissues.
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Page 8 of 11Table 4 Quantitative RT-PCR analysis of lung NEPS genes and select previously identified genes
Gene Symbol* Cumulative Rank dCt Variance Rank NormFinder Stability Value Rank geNorm
M value
Rank
NDUFA1 11 2.011 4 0.059 2 1.141 5
RPL19 14 2.252 6 0.071 4 1.140 4
RAB5C 18 2.928 10 0.058 1 1.150 7
RPS18 20 0.011 1 0.064 3 1.461 16
TBP 24 3.846 16 0.076 7 1.097 1
RPL4 27 1.523 3 0.099 12 1.253 12
ATP5J 28 2.150 5 0.090 9 1.342 14
HMGB1 29 2.648 8 0.093 10 1.210 11
TRIM27 29 3.752 15 0.073 5 1.158 9
EIF4A2 31 3.229 12 0.106 16 1.131 3
CAPZB 33 4.362 18 0.100 13 1.105 2
PPP1CB 33 3.453 13 0.104 14 1.143 6
CUL1 34 5.164 20 0.075 6 1.156 8
ACTB 37 2.731 9 0.099 11 1.638 17
B2M 38 1.517 2 0.154 21 1.369 15
HPRT1 39 3.611 14 0.105 15 1.173 10
CSTB 41 3.026 11 0.108 17 1.259 13
CD55 44 2.460 7 0.131 18 1.811 19
HSPA1A 47 7.330 21 0.077 8 1.653 18
GAPDH 58 4.044 17 0.145 20 2.093 21
SLFN13 58 4.803 19 0.132 19 1.858 20
*Genes identified in this study are bolded
Figure 3 SAM and pathway analysis of a dataset normalized with and without lung NEPS genes. (A) Number of probes identified as
differentially over and underexpressed between cancer and normal using SAM on the dataset with and without NEPS normalization. Venn diagram
illustrates the overlap in the genes identified as well as those which are different between the two analyses. (B) Canonical pathway analysis using
Ingenuity Pathway Analysis. Dark blue bars represent the results from the dataset normalized with MAS 5.0 + NEPS and light blue bars represent the
results from normalization using MAS 5.0 alone. The pathways which are the most significant are the most significant in both analyses. Note that key
pathways such as Neuregulin signaling and JAK/Stat are identified with higher significance when normalized using the lung NEPS genes. Such
differences illustrate the impact of reference gene selection and normalization on differential gene expression analysis.
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Additional file 1: Summary of lung SAGE libraries. Raw tag count
summary for lung SAGE libraries used in analysis.
Additional file 2: Summary of breast SAGE libraries. Raw tag count
summary for breast SAGE libraries used in analysis.
Additional file 3: Summary of brain SAGE libraries. Raw tag count
summary for brain SAGE libraries used in analysis.
Additional file 4: Taqman probe IDs of genes assessed by
quantitative RT-PCR. Applied Biosystems Taqman probe IDs for genes
assessed by qRT-PCR.
Additional file 5: Probes used for NEPS genes represented on the
Affymetrix U133A microarray. Probes for NEPS genes represented on
the Affymetrix U133A microarray.
Additional file 6: Probes used for NEPS genes represented on the
Agilent microarray. Probes used for NEPS genes represented on the
Agilent microarray.
Additional file 7: Permutation scores of previously identified and
NEPS identified reference genes. Data used in scatter plot shown in
Figure 1.
Additional file 8: Ingenuity Pathway Analysis using genes from the
analyses of a NEPS-normalized and unnormalized dataset by Landi
et al. Ingenuity Pathway Analysis using genes from the analyses of a
NEPS-normalized and unnormalized dataset by Landi et al.
Additional file 9: SAM and pathway analysis of an Agilent lung
cancer microarray dataset normalized with and without lung NEPS
genes. SAM and pathway analysis of a dataset normalized with and
without lung NEPS genes. (A) Number of probes identified as
differentially over and underexpressed between cancer and normal using
SAM on the dataset with and without NEPS normalization. Venn diagram
illustrates the overlap in the genes identified as well as those which are
different between the two analyses. (B) Canonical pathway analysis using
Ingenuity Pathway Analysis. Dark blue bars represent the results from the
dataset normalized with NEPS and median normalization and light blue
bars represent the results from using median normalization alone. While
similar pathways are statistically significant, each pathway is slightly
different in the degree of statistical significance. Such differences
illustrate the impact of reference gene selection and normalization on
differential gene expression analysis.
Additional file 10: Ingenuity Pathway Analysis using genes from the
analyses of a NEPS-normalized and unnormalized dataset by
Boelens et al. Ingenuity Pathway Analysis using genes from the analyses
of a NEPS-normalized and unnormalized dataset by Boelens et al.
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